p53 status does not predict initial clinical response to bacillus calmette-guerin intravesical therapy in T1 bladder tumors

Journal of Urology

Volumn 159, Issue 3, 1998, Pages 1079-1084

  Pages, Franck ^b   Flam, Thierry A ^b   Vieillefond, Annick ^b   Molinie, Vincent ^b   Abeille, Xavier ^b   Lazar, Vladimir ^b   Bressac de Paillerets, Brigitte ^b   Mosseri, Veronique ^b   Zerbib, Marc ^b   Fridman, Wolf H ^b   Debré, Bernard ^b   Thiounn, Nicolas ^a  

^a Hôpital Cochin ^*  (France)

^b NONE

Author keywords

BCG vaccine; Bladder neoplasms; Gene; P53; Prognosis

Indexed keywords

BCG VACCINE; DNA; MONOCLONAL ANTIBODY; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; INTRAVESICAL DRUG ADMINISTRATION; MALE; PREDICTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; SMOKING; TRANSURETHRAL RESECTION; TUMOR SUPPRESSOR GENE;

EID: 0031932476     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)63839-4     Document Type: Article

References (21)

1. Herr, H. W., Wartinger, D. D., Fair, W. R. and Oettgen, H. F.: Bacillus Calmette-Gu 233 rin therapy for superficial bladder cancer: a 10-year followup. J. Urol., 147: 1020, 1992.
2. Herr, H. W.: Progression of stage Tl bladder tumors after intravesical bacillus Calmette-Gu 233 rin. J. Urol., 145: 40, 1991.
3. Esrig, D., Elmajian, D., Groshen, S., Freeman, J. A., Stein, P. J., Chen, S. C., Nichols, P. W., Skinner, D. G., Jones, P. A. and Cote, R. J.: Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med., 331: 1259, 1994.
4. Ko, L. J. and Prives, C.: p53: puzzle or paradigm. Genes Dev., 10: 1054, 1996.
5. Soussi, T., Legros, Y., Lubin, R., Ory, K. and Schlichtholz, B.: Multifactorial analysis of p53 alteration in human cancer: a review. Int. J. Cancer, 57: 1, 1994.
6. Kuczyk, M. A., Serth, J., Hervatin, C., Arndt, H., Derendorf, L., Thon, W. F. and Jonas, U.: Detection of p53 tumor suppressorgene protein in bladder tumors and prostate cancer; possible clinical implication. World J. Urol., 12: 345, 1994.
7. Uchida, T., Wada, C., Ishida, H., Wang, C., Egawa, S., Yokoyama, E., Kameya, T. and Koshiba, K.: p53 mutations and prognosis in bladder tumors. J. Urol., 153: 1097, 1995.
8. Wright, C., Thomas, D., Mellon, K., Neal, D. E. and Home, C. H.: Expression of retinoblastoma gene product and p53 protein in bladder carcinoma; correlation with Ki67 index. Br. J. Urol., 75: 173, 1995.
9. Thomas, D. J., Robinson, M. C., Charlton, R., Wilkinson, S., Shenton, B. K. and Neal, D. E.: p53 expression, ploidy and progression in pT1 transitional cell carcinoma of the bladder Br. J. Urol., 73: 533, 1993.
10. Gardiner, R. A., Walsh, M. D., Allen, V., Rahman, S., Samaratunga, M. L. T. H., Seymour, G. J. and Lavin, M. F.: Immunohistological expression of p53 in primary pT1 transitional cell bladder cancer in relation to tumour progression Br. J. Urol., 73: 526, 1994.
11. Sarkis, A. S., Dalbagni, G., Cordon-Cardo, C., Zang, Z. F., Sheinfeld, J., Fair, W. R., Herr, H. W. and Reuter, V. E.: Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J. Natl. Cancer Inst., 85: 53, 1993.
12. Serth, J., Kuczik, M. A., Bokemeyer, C., Hervatin, C., Nafe, R., Tan, H. K. and Jonas, U.: p53 immunohistochemistry as independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br. J. Cancer, 71: 201, 1995.
13. Lacombe, L., Dalbagni, G., Zhang, Z. F., Cordon-Cardo, C., Fair, W. R., Herr, H. W. and Reuter, V. E.: Overexpression of p53 protein in a high risk population of patients with superficial bladder cancer before and after Bacillus Calmette-Gu 233 rin therapy: correlation to clinical outcome. J. Clin. Oncol., 10: 2646, 1996.
14. Sarkis, A. S., Dalbagni, G., Cordon-Cardo, C., Melamed, J., Zhang, Z. F., Sheinfeld, J., Fair, W. R., Herr, H. W. and Reuter, V. E.: Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J. Urol. 152: 388, 1994.
15. Appleman, L. J. and Frey, A. B.: Dominant-negative p53 can restore tumorigenicity of L-929 cells in immunocompetent mice. Int. J. Cancer, 63: 576, 1995.
16. Spruck III, C. H., Ohneseit, P. F., Gonzalez-Zulueta, M., Esrig, D., Miyao, N., Tsai, Y. C., Lerner, P. S., SchmŸtte, C., Yang, A. S., Cote, R., Dubeau, L., Nichols, P. W., Hermann, G. G., Steven, K., Horn, T., Skinner, D. G. and Jones, P. A.: Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res., 54: 784, 1994.
17. Curigliano, G., Zhang, Y. J., Wang, L. Y., Flamini, G., Alcini, A., Ratto, C., Giustacchini, M., Alcini, E., Cittadini, A. and Santella, R. M.: Immunohistochemical quantitation of 4-aminobiphenyl-DNA adducts and p53 nuclear overexpression in T1 bladder cancer of smokers and nonsmokers. Carcinogenesis, 17: 911, 1996.
18. Prescott, S., James, K., Busittil, A., Hargreave, T. B., Chisholm, G. D. and Smyth, J. F.: HLA DR expression by high grade superficial bladder cancer treated with BCG. Br. J. Urol., 63: 264, 1989.
19. De Reijke, T. M., De Boer, E. C., Kurth, K. H. and Schamhart, D. H.: Urinary cytokines during intravesical bacillus Calmette-Gu 233 rin therapy for superficial bladder cancer: processing, stability and prognostic value. J. Urol., 115: 488 1996.
20. Eder, I. E., Stenzl, A., Hobisch, A., Cronauer, M. V., Bartsch, G. and Klocker, H.: Transforming growth factors-beta 1 and beta 2 in serum and urine from patients with bladder carcinoma J. Urol., 156: 953, 1996.
21. Lazar, V., Grandjouan, S., Bognel, C., Couturier, D., Rougier, P., Bellet, D. and Bressac-de Paillerets, B.: Accumulation of multiple mutations in tumor suppressor genes during colorectal tumorigenesis in HNPCC patients. Hum. Mol. Genet., 12: 2257, 1994.